abbv-47d11 + abbv-2b04

**ABBV-47D11 + ABBV-2B04** is a combination of two investigational monoclonal antibodies developed by AbbVie for the treatment of COVID-19. These antibodies specifically target distinct, mutationally conserved regions on the **SARS-CoV-2 spike protein**, with neutralizing activity evident against the virus in preclinical and Phase 1 studies. ABBV-47D11 is described as binding to a hydrophobic pocket distal to the ACE2 binding site on the spike protein. The combination was studied for safety, pharmacokinetics, and pharmacodynamics as intravenous infusions in adults with COVID-19, evaluating anti-viral activity, immunogenicity, and tolerability. The goal is to prevent viral entry and replication by direct neutralization of SARS-CoV-2[1][2][3][4][5][6].